Cost of Revenue Comparison: Vertex Pharmaceuticals Incorporated vs Supernus Pharmaceuticals, Inc.

Vertex vs Supernus: A Decade of Cost Dynamics

__timestampSupernus Pharmaceuticals, Inc.Vertex Pharmaceuticals Incorporated
Wednesday, January 1, 2014575800060987000
Thursday, January 1, 20158423000125542000
Friday, January 1, 201611986000210460000
Sunday, January 1, 201715215000275119000
Monday, January 1, 201815356000409539000
Tuesday, January 1, 201916660000547758000
Wednesday, January 1, 202052459000736300000
Friday, January 1, 202175061000904200000
Saturday, January 1, 2022872210001080300000
Sunday, January 1, 2023837790001262200000
Monday, January 1, 20241530500000
Loading chart...

Unleashing insights

Cost of Revenue: A Tale of Two Pharmaceutical Giants

In the competitive landscape of pharmaceuticals, understanding cost structures is crucial. Over the past decade, Vertex Pharmaceuticals Incorporated and Supernus Pharmaceuticals, Inc. have showcased contrasting trajectories in their cost of revenue. From 2014 to 2023, Vertex's cost of revenue surged by over 1,900%, reflecting its aggressive expansion and investment in cutting-edge treatments. In contrast, Supernus Pharmaceuticals experienced a more modest increase of approximately 1,350%, indicating a steady growth strategy.

Key Insights

  • Vertex Pharmaceuticals: By 2023, Vertex's cost of revenue reached a staggering 1.26 billion, a testament to its commitment to innovation and market leadership.
  • Supernus Pharmaceuticals: Despite a smaller scale, Supernus's cost of revenue grew consistently, peaking at 87 million in 2022, highlighting its focus on niche markets.

These trends underscore the diverse strategies employed by pharmaceutical companies to navigate the ever-evolving healthcare landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025